Baird lowered the firm’s price target on Healthpeak Properties (DOC) to $21 from $22 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results where a difficult lab quarter took the spotlight.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOC:
- Healthpeak Properties downgraded at Scotiabank amid lab challenges
- Healthpeak downgraded to Sector Perform from Outperform at Scotiabank
- Healthpeak Properties’ Earnings Call: Mixed Sentiment and Strategic Growth
- Positive Outlook for Healthpeak Properties: Buy Rating Affirmed Amid Solid Q2 Performance and Stable Financial Position
- Healthpeak Properties Reports Steady Q2 2025 Results